Please login to the form below

Not currently logged in
Email:
Password:

Zogenix appoints Pfizer’s R Scott Shively as chief commercial officer

Was VP global commercial disease area lead for pain at Pfizer

Pain specialist Zogenix has appointed former Pfizer VP R Scott Shively as its new chief commercial officer.

Shively has experience in the therapy area, serving as VP global commercial disease area lead for pain at Pfizer, and we will have responsibility for all of Zogenix' commercial strategies and operations.

This includes ensuring the success of current products, such as Sumavel DosePro for migraine, as well as soon to be launched products, such as Zohydro, which is pending FDA approval for the treatment of chronic pain.

“We have the potential of launching a new product, expanding our commercial organisation and pursuing a range of corporate development opportunities," said Roger Hawley, CEO of Zogenix.

"Scott's commercial expertise will add important depth and breadth to our executive team. He understands our vision as well as the challenges and opportunities we face.”

Prior to his most recent role at Pfizer, Shively spend a year at the US pharma firm as VP, global commercial medicine team leader.

Other previous positions include senior VP commercial operations at pain specialists Alpharma Pharmaceuticals, VP marketing at Endo Pharmaceuticals and VP global strategy and commercial development at Mallinckrodt.

He said: “I believe my experience, not only in the pain market but also with partnering opportunities and successfully building brands, will provide benefits now and into the next phase of the company's growth. It's an exciting time to join and to make a contribution to the ongoing success of Zogenix."

28th November 2012

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

Robust Review: COVID19 Assessment
See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
Human behaviour - Sept 21
All change – how untangling human behaviour can encourage better health
Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...